On Tuesday, Emergent BioSolutions Inc. EBS reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the consensus of $190 million. The company reported an adjusted EPS loss of $(2.32), more than double the $(1.05) reported a year ago, missing the consensus of $(0.94). Revenues from Narcan (naloxone HCl) Nasal Spray decreased 10% to $120 million, primarily driven by an unfavorable price and volume mix in 2024 to U.S. public interest channels and lower Canadian market sales, part ...

Emergent BioSolutions Inc. (NYSE:EBS) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Joe Papa - President and CEO Rich Lindahl - EVP and CFO Paul Williams - SVP, Products Business Conference Call Participants Operator Good afternoon, everyone. I'm the operator for today's call. Thank you for joining today as Emergent discusses their Operational and Financial Results for the Second Quarter of 2024. As is customary, today's call is open to all participants, and the call is bei ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 300 Professional Drive Gaithersburg, MD 20879 Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

| --- | --- | |----------------|-------| | | | | | | | | | | | | | Q2 2024 | | | Financial | | | Results | | | Update | | | | | | | | | | | | | | | August 6, 2024 | | | | | | | | | | | | | | | | | | | | PROPRIETARY AND CONFIDENTIAL Q2 2024 Update Introduction INTRODUCTION Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statemen ...

Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance range Second Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) million Updates FY 2024 guidance GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2024. "In the first half of the year, we made great progress to stabilize our financial position by strategically divesting assets, resolving several leg ...

EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS • Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance range • Second Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) million • Updates FY 2024 guidance GAITHERSBURG, Md., August 6, 2024—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2024. "In the first half of the year, we made great progress to stabilize our financial position b ...

Company Overview - SERB Pharmaceuticals has acquired RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. for approximately $75 million, with an additional $5 million milestone payment [2] - The acquisition strengthens SERB's position as a leading provider of medical countermeasures for chemical, biological, radiological, and nuclear threats [4] - SERB has a broad portfolio of antidotes and preventive medicines, enhancing opportunities to partner with governments, militaries, NGOs, and emergency preparedness agencies globally [4][7] Product Details - RSDL® is a medical device designed to remove or neutralize chemical warfare agents from the skin, including tabun, sarin, soman, and mustard gas [1][8] - It is the only FDA-cleared device backed by 20 years of clinical data, capable of performing its function in one step [1] - Over 15 million packets of RSDL® have been sold in more than 30 countries [1] Operational Aspects - As part of the acquisition, SERB will operate the leased manufacturing facility in Hattiesburg, Mississippi, and retain several employees supporting the RSDL® product [2] - RSDL® was initially developed by Defence Research and Development Canada to prepare Canadian forces for chemical warfare attacks and has received multiple international approvals [4]

Company Overview - SERB Pharmaceuticals is a global specialty pharmaceutical company with a focus on emergency care and rare diseases, boasting the broadest antidote portfolio for chemical, biological, radiological, and nuclear (CBRN) risks [6][9] - The company has over 30 years of experience in treating complex and life-threatening conditions, supporting healthcare systems and governments while providing hope to patients and their families [6] Acquisition Details - SERB Pharmaceuticals announced the acquisition of RSDL® (Reactive Skin Decontamination Lotion) from Emergent BioSolutions Inc. for an up-front payment of approximately $75 million, with an additional $5 million milestone payment [8] - As part of the acquisition, SERB will operate the leased manufacturing facility in Hattiesburg, Mississippi, and several employees supporting the RSDL® product will join SERB [8] Product Information - RSDL® is a medical device designed to remove or neutralize chemical warfare agents from the skin, with FDA clearance and over 20 years of clinical data supporting its efficacy [1][3] - The product has sold over 15 million packets across more than 30 countries, highlighting its global reach and acceptance [1] Strategic Importance - The acquisition of RSDL® enhances SERB's position as a leading provider of medical countermeasures for CBRN threats, creating new opportunities for collaboration with governments, militaries, NGOs, and emergency preparedness agencies worldwide [9]

"For years, our colleagues have proudly manufactured, sold and distributed RSDL® to many branches of the U.S. government to ensure military personnel safety and public health preparedness," said Joe Papa, president and chief executive officer at Emergent. "SERB is a well-positioned global leader that is expected to continue to make RSDL® readily available for the U.S. and allied governments." RSDL®is anFDA-cleared device provided as kit consisting of a lotion impregnated sponge in a packet, it is intended t ...

This transaction follows Emergent's announcement to sell its drug product facility in Baltimore-Camden, as well as operational changes, which are key actions in its multi-year plan. The net proceeds from the sale of RSDL® and the Baltimore-Camden facility will reduce or eliminate the Junior Capital Raise requirements under Emergent's amended credit facility, a requirement that was recently extended to September 29, 2024. At Emergent, our mission is to protect and enhance life. For 25 years, we've been at wo ...